Survey on Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer
Lung cancer has been the leading cancer worldwide, which can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on biology, therapy, and prognosis. NSCLC accounts for more than 85% of all lung cancer cases and has a poor prognosis with only 15% of all lung cancer patients alive 5 years or more after diagnosis.
Traditional Chinese medicine (TCM) originated from Chinese philosophy is a different medical system from conventional western medicine. It focuses on health maintenance and emphasizes on harmonizing the imbalance of body. Current studies show that TCM has the advantages of increasing the sensitivity of chemo- and radio-therapeutics, reducing the side effects and chemo- and radio-therapeutics associated complications, improving patients' quality of life and survival time. However, how TCM can work with conventional medicine for the treatment of carcinoma is still an important research topic worldwide. Syndrome, the essential concept in TCM theory, is a diagnostic conclusion of the pathological changes at a certain stage of a disease, including the location, cause, and nature as well as the trend of development.
This study aims to investigate the distribution of TCM syndromes, the changing pattern among NSCLC patients before and after having surgery, chemotherapy and radiation therapy, and the correlations with patient quality of life and progression free survival. The results are important for establishing guidelines for TCM practice and research in future.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Changing Pattern of Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer in Hong Kong: A Longitudinal Survey|
- Changes of TCM syndromes [ Time Frame: Baseline (Pre-operation) and 1 week (Post-operation) ] [ Designated as safety issue: No ]
- Changes of TCM syndromes [ Time Frame: Baseline, Post chemotheray/radiation therapy, 3rd month, 6th month, 9th month, 12th month, 15th month, 18th month, 21month, 24month ] [ Designated as safety issue: No ]
- QoL assessment [ Time Frame: Post operation therapy, Post chemotheray/radiation therapy, 3rd month, 6th month, 9th month, 12th month, 15th month, 18th month, 21month, 24month ] [ Designated as safety issue: No ]using validated QLQ-C30 and QLQ-LC13 (Cantonese Hong Kong version)
- Progression free survival [ Time Frame: 3rd month, 6th month, 9th month, 12th month, 15th month, 18th month, 21th month, 24th month ] [ Designated as safety issue: No ]
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
|NSCL cancer patients|
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01681485
|Queen Elizabeth Hospital||Recruiting|
|Hong Kong, China|
|Contact: Hollie CW Cheng, Mphil (852) 2958 7847 firstname.lastname@example.org|
|Contact: Peter PF So, MD (852) 2958 2307 email@example.com|
|Principal Investigator: Peter PF So, MD|
|Principal Investigator:||Peter PF So, MD||Queen Elizabeth Hospital|